Drug Profile


Alternative Names: CNS 1102

Latest Information Update: 18 Dec 2001

Price : $50

At a glance

  • Originator CeNeS Pharmaceuticals
  • Class Anti-ischaemics; Guanidines; Neuroprotectants
  • Mechanism of Action Glutamate receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Brain injuries; Stroke

Most Recent Events

  • 18 Dec 2001 A study has been added to the adverse events and therapeutic trials sections
  • 07 Dec 2001 Discontinued-III for Stroke in USA (IV)
  • 16 Feb 2001 Cambridge NeuroScience is now called CeNeS Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top